The Calm Claims FDA Listed as Acceptable

which calm and stress phrases did fda name as acceptable?

FDA named eleven exact calm and stress phrases as acceptable structure/function claims, and it did so in its own words inside the January 2000 final rule preamble on dietary supplement claims. We pulled the list straight from that text instead of summarizing it, because the wording itself is the reusable asset here.

These eleven come from FDA's review of the OTC daytime-sedative monograph — the same rulemaking that also hands sleep marketers their permitted vocabulary. If you write for both categories, the phrasing rules travel together: FDA applies the same 'occasional' framing to sleeplessness that it applies here to stress.

• "Occasional simple nervous tension"
• "Nervousness due to common every day overwork and fatigue"
• "A relaxed feeling"
• "Calming down and relaxing"
• "Gently soothe away the tension"
• "Calmative"
• "Resolving that irritability that ruins your day"
• "Helps you relax"
• "Restlessness"
• "Nervous irritability"
• "When you're under occasional stress, helps you work relaxed"

why did fda say those particular phrases pass?

FDA said the phrases pass because each one describes an occasional or transient state rather than a diagnosed, chronic condition — duration is the test, not the emotion named. In the agency's own words, the list works "because all suggest occasional rather than long-term or chronic mood changes," per FDA's final rule preamble.

The same commonness-and-severity test runs the whole rule, not just calm copy. Under 21 CFR 101.93(g)(2)(iii), a statement only becomes a disease claim when it describes an abnormal condition that is uncommon or can cause significant or permanent harm, and FDA has said it would ordinarily treat a condition as common if more than half the people going through that life stage or process experience it. Ordinary stress from a rough week at work clears both bars easily — it's neither rare nor permanently damaging — so a claim about relieving it stays outside disease territory. An anxiety disorder doesn't clear those bars: it's a diagnosable condition with clinical criteria, and describing its treatment, or its characteristic signs and symptoms, converts the identical sentence into a disease claim no matter how softly it's phrased.

Stress and frustration aren't disease symptoms on their own; anxiety disorder is a disease by name.

does the list cover 'nervous irritability' and 'restlessness' too?

Yes — "restlessness" and "nervous irritability" both sit on FDA's list word for word, next to "resolving that irritability that ruins your day." All three describe a passing state rather than a named disorder, which is exactly why FDA let them through the same door as "a relaxed feeling."

FDA has run this narrow-list exercise before. It named a similarly short set of approved phrases for digestive complaints using the identical logic — descriptive of a common, temporary symptom rather than a disease. The vocabulary changes by niche; the method behind it doesn't.

Restlessness is safe; restless legs syndrome is not.

how far can 'helps you relax' be stretched before it breaks?

"Helps you relax" breaks the moment it stops describing a passing state and starts implying treatment of a diagnosed condition — the words can stay almost identical while the legal category changes underneath them. Naming the disorder, not the intensity of the feeling, is what does the damage.

The product name carries the same risk as the body copy. FDA's own textbook example is "Herbal Prozac," which it treats as a claim that the product "is a substitute for a product that is a therapy for a disease" under 21 CFR 101.93(g)(2)(vi) — the same rule that catches "nature's Xanax" on a bottle label.

is 'supports mood' inside the same permission?

Yes — "supports mood" sits inside the same permission, and FDA explained exactly why in the same preamble. The agency wrote that "to substantiate the claim 'supports mood,' it is not necessary to study the effects of a substance on clinical depression," because ordinary mood variation and clinical depression are different things to measure.

That's a genuinely contestable point in this industry: most advertisers treat "supports mood" and "helps you relax" as interchangeable filler phrases, but FDA's own reasoning ties each one to a different kind of study. Swap the phrase without swapping the evidence file behind it, and the claim you're substantiating stops matching the claim you're making — you can build a mood study on healthy volunteers reporting day-to-day swings and stay inside "supports mood," but you can't borrow that same file for language that implies you're treating a depressive disorder.

why does borrowing a clinical-depression study undercut a permitted mood claim?

Borrowing a clinical-depression study undercuts a permitted mood claim because the population you tested becomes the population your claim gets read against — a depressed-cohort trial signals a depression claim no matter what the label says. We checked this against FDA's and FTC's separate tests, and both point the same direction: substantiation evidence and label wording have to describe the same condition.

Evidence follows the population you tested, not the label you wrote.

This is also where the live enforcement record sits. FTC's June 2026 complaint against Amare Global Holdings alleges its brand partners claimed the supplements would "lower, reduce, or regulate cortisol" and "raise, increase, or normalize serotonin, dopamine and GABA," framing that reads as clinical no matter how the base product is labeled; the case remains pending.

what still has to be substantiated even when the wording is allowed?

Lawful wording under FDA doesn't touch FTC's separate substantiation bar — you still need competent and reliable scientific evidence behind whatever you claim, wording aside. FTC's own guidance states that "substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing," and animal or in vitro data alone doesn't clear that bar.

There's also no shortcut through FDA's authorized health-claim list. None of FDA's twelve significant-scientific-agreement health claims — the same short list that covers the cholesterol and heart-disease claims FDA actually authorized — reaches mood, stress or anxiety, so structure/function is the only lawful route in this niche, not one option among several.

On April 13, 2023 FTC sent penalty-offense notices to roughly 670 supplement and OTC marketers, warning of civil penalties up to $50,120 per violation for claims lacking that evidence — receiving one of those notices doesn't change the wording rules, but it raises the cost of getting the evidence wrong.

where does meta's personal-attributes rule cut the list shorter than fda does?

Meta's personal-attributes rule cuts the list shorter than FDA does by banning the second-person diagnosis framing that FDA's wording would otherwise allow. A fully lawful "helps you relax" ad still can't say "your anxiety" or ask "stressed out again?" — that's a platform rule, not a claims rule, and it usually stops the campaign before FDA or FTC ever look at it. Because an estimated 19.1% of US adults have some anxiety disorder in a given year, per NIMH survey data collected in the early 2000s, Meta's mental-health caution touches a wide slice of any wellness remarketing list.

Meta's own Privacy Violations and Personal Attributes policy bars ads that assert or imply an audience member's "physical or mental health (including medical conditions)," contrasting the compliant "Depression counseling" against the non-compliant "Depression getting you down? Get help now." Category language passes; naming the viewer's condition doesn't.

We could not re-verify Meta's live policy page this session — it renders through JavaScript and returned no readable text on the fetch we ran — so treat this section as our last confirmed reading, dated August 4, 2026, and pull the live page yourself before a launch depends on it.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Kidney Offers: The Highest Claim Risk in Nutra, Mapped, Thyroid Offers: Market Structure, Buyer, and Claim Ceiling, Sleep Offers: Insomnia Demand Inside a Structure/Function Ceiling, Mood and Calm Offers: Selling Around a Mental Health Diagnosis, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.